P&G Health Ltd (formerly Procter & Gamble td) (erstwhile Merck Limited) is engaged in the business of manufacturing and marketing of pharmaceuticals and chemicals.
The company possesses a wide moat built on legacy pharmaceutical brands like Neurobion and Evion that enjoy high trust and prescription dominance among healthcare professionals. This is corroborated by exceptionally high and stable ROCE (38.5%) and net margins (23.7%), indicating that the brand equity translates into significant pricing power and market insulation.
Management follows a disciplined, asset-light strategy, focusing on productivity to fund brand reinvestment. Excess cash is consistently returned to shareholders via substantial dividends, as evidenced by the high payout ratios and lack of debt.
The investment collapsed because the parent company's control over the product pipeline and raw materials turned from a benefit into a siphon. Over five years, the related-party transactions for technology and sourcing escalated, effectively transferring the local entity's margins back to the global parent. Simultaneously, the heavy reliance on a few super-distributors created a bottleneck; when these partners faced credit crunches or demanded higher cuts, the company's asset-light model left it with no physical infrastructure to bypass them, leading to a permanent reset of the net margin profile.
RichFakir rates Procter & Gamble Health Ltd's business quality as decent — 67/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as wide.
On our model, Procter & Gamble Health Ltd is trading far above our estimate of fair value (expensive on our lens); we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Procter & Gamble Health Ltd is: Watch — wait for price. A decent business, but at an expensive price against our estimate of fair value — one to keep on the watchlist for a better entry.
RichFakir's educational estimate of Procter & Gamble Health Ltd's fair value is about ₹1,840 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →